Establishing and operating a ‘virtual ward’ system to provide care for patients with COVID-19 at home: experience from The Gambia


ABSTRACT

Health systems in sub-Saharan Africa have remained overstretched from dealing with endemic diseases, which limit their capacity to absorb additional stress from new and emerging infectious diseases. Against this backdrop, the rapidly evolving COVID-19 pandemic presented an additional challenge of insufficient hospital beds and human resource for health needed to deliver hospital-based COVID-19 care. Emerging evidence from high-income countries suggests that a ‘virtual ward’ (VW) system can provide adequate home-based care for selected patients with COVID-19, thereby reducing the need for admissions and mitigate additional stress on hospital beds. We established a VW at the Medical Research Council Unit, The Gambia at the London School of Hygiene and Tropical Medicine, a biomedical research institution located in The Gambia, a low-income west African country, to care for members of staff and their families infected with COVID-19. In this practice paper, we share our experience focusing on the key components of the system, how it was set up and successfully operated to support patients with COVID-19 in non-hospital settings. We describe the composition of the multidisciplinary team operating the VW, how we developed clinical standard operating procedures, how clinical oversight is provided and the use of teleconsultation and data capture systems to successfully drive the process. We demonstrate that using a VW to provide an additional level of support for patients with COVID-19 at home is feasible in a low-income country in sub-Saharan Africa. We believe that other low-income or resource-constrained settings can adopt and contextualise the processes we have described in this practice paper to provide an additional level of support for patients with COVID-19 in non-hospital settings.

INTRODUCTION

From the time it was first confirmed in December 2019, COVID-19 has spread to six continents, with more than 119 million cases and 2.6 million deaths registered as of mid-March 2021. The first case of COVID-19 in Africa was confirmed on 14 February 2020 in Egypt and by mid-April 2020, there were already 19895 cases reported across 52 of the 54 countries in the continent. As with other pandemics, the COVID-19 pandemic has had direct and indirect effects on populations in every country. While the reported effects on morbidity and mortality appear to be less intense in some countries, the staggering levels of morbidity and mortality in other countries together with the increased need for facility care have severely stretched, in some cases overwhelmed, their health systems—irrespective of the per capita gross national income.

Health systems in Africa were already stretched thin from dealing with endemic infectious disease, non-communicable diseases, maternal and child health issues...
prior to the onset of the COVID-19 pandemic. In this context, their capacity to absorb additional stress from a widespread outbreak was limited. Early mathematical models had suggested that Africa could be the most vulnerable continent. It was also anticipated that higher incidence of severe forms of COVID-19 could occur in Africa due to the high prevalence of conditions that impair the immune system: tuberculosis, HIV/AIDS, malaria, anaemia and underlying malnutrition. Furthermore, there was the additional challenge of insufficient critical care beds and human resources for health (HRH) needed to support severe forms of COVID-19. This led to shifts of HRH from other areas to support COVID-19 care, thus creating shortages of clinical staff to support routine health services. The shortages of HRH needed to sustain routine services have dire consequences such as the reduction in maternal, newborn and child health services, which might halt progress towards global health targets.

As the pandemic progressed, there was a reorganisation of the health service delivery systems to mitigate the potential impact of the crisis. While there is a global consensus regarding the general principles of prevention and case management, many countries have also implemented context specific strategies that suited their local realities, such as the adoption of digital communication tools to deliver safe virtual care for COVID-19 patients and to coordinate the response to the pandemic. Digital health or telemedicine holds enormous promise and has been shown to reduce the need for admissions and mitigate pressure on hospital beds. However, the focus of existing literature on COVID-19 VW systems has been the clinical outcomes associated with the system, with less on the experience and processes involved in setting up and operationalising such systems. To the best of our knowledge, there is no literature describing the use of the VW system to support patients with COVID-19 in sub-Saharan African countries. In this practice paper, we hope to bridge this important gap by sharing our experience of setting up and operating a VW system to provide care for patients with COVID-19 in a biomedical research institution in The Gambia, West Africa.

**SETTING AND CONTEXT**

The Gambia is a low-income west African country, with a per capita health expenditure in 2017 of US$23 and has a population of 2.1 million people. There are estimated 11 hospital beds per 10,000 of the population and one physician per 10,000 of the population as of 2015. The first case of COVID-19 in The Gambia was confirmed on 17 March 2020 as an imported case in an adult female. By the end of June 2020, just over 3 months since the index case was confirmed, only 48 additional cases were detected in the country. However, between July 2020 and September 2020, the number of cases rapidly increased and peaked, with 3579 COVID-19 cases (ie, 15 cases per 10,000 population) confirmed by the end of September 2020 (Figure 1).

Until late August 2020, the national case management policy specified that all confirmed COVID-19 cases be isolated in government designated treatment centres where they would be managed until they tested negative twice before discharge. Individuals who were considered to have been significant contacts of positive cases were also quarantined in designated hotels at no personal cost. As the number of confirmed cases peaked, there was a significant strain on hospital beds at the designated national treatment centres. This situation was due, in part, to the national criteria that required in-hospital care for all confirmed cases and two negative SARS-CoV-2 PCR test before their discharge from in-hospital care. There was, however, a national change to the WHO symptomatic criteria for releasing patients with COVID-19 from isolation in late August 2020.

The Medical Research Council Unit The Gambia at London School of Hygiene and Tropical Medicine (MRCG at LSHTM) is a biomedical research institution operational in The Gambia for more than 70 years and has over 1300 employees. The MRCG at LSHTM has a 42-bed Clinical Services Department (CSD), which provides outpatient and inpatient clinical care for its patients. The use of the VW system to support patients with COVID-19 has been implemented in the USA and UK and has been shown to reduce the need for admissions and mitigate pressure on hospital beds. However, the focus of existing literature on COVID-19 VW systems has been the clinical outcomes associated with the system, with less on the experience and processes involved in setting up and operationalising such systems. To the best of our knowledge, there is no literature describing the use of the VW system to support patients with COVID-19 in sub-Saharan African countries. In this practice paper, we hope to bridge this important gap by sharing our experience of setting up and operating a VW system to provide care for patients with COVID-19 in a biomedical research institution in The Gambia, West Africa.
staff and their relatives, study participants and the local population. Apart from these responsibilities, the CSD is one of only two hospital facilities in The Gambia that supports inpatient management of patients with severe COVID-19. As part of a wider COVID-19 preparedness, at the beginning of the pandemic, the MRCG at LSHTM made several changes to its clinical systems in the CSD such as setting up an additional 30 beds for patients with COVID-19. A comprehensive reorganisation of inpatient and outpatient services, development of operational and clinical guidelines with training, and establishment of a consultant-led multidisciplinary team to provide dedicated COVID-19 care was also done.

Four months after the index case was confirmed in The Gambia, the first case of COVID-19 among an MRCG at LSHTM staff was identified on 18 July 2020 and cases subsequently increased rapidly as illustrated in figure 1. After the confirmation of the first staff case, the MRCG at LSHTM constituted a Staff COVID-19 Risk Coordination (SCRIC) team on 23 July 2020 to coordinate responses and actions and ensure the highest possible safety standards for staff. The SCRIC team commenced operation of the VW system when it became apparent that the hospitalisation of all asymptomatic and symptomatic COVID-19 cases, as was the procedure at the time, was not sustainable because it added intense pressure on the limited CSD beds and frontline HRH. See figure 2 showing the timeline of the key events leading up to the establishment and operationalisation of the VW system.

THE REMIT OF THE ‘VIRTUAL WARD’ SYSTEM

The objectives of the VW system is to provide home-based support for a subset of COVID-19 cases meeting certain criteria, ensure they are closely monitored and escalate if they deteriorate, thereby avoiding unnecessary hospital admission for COVID-19. The eligibility criterion for our VW system is a primary diagnosis of COVID-19 in patients who have not already been admitted to the hospital. Such patients must have asymptomatic or mild/moderate symptoms of the disease and be staff members (or their immediate relatives) who, based on their clinical presentation and assessment of risk factors by a clinician, are at low risk of progressive disease. Because our VW system requires that patients be primarily isolated at home, another eligibility requirement is that the home and social setting must be ideal for home isolation.

The key components of our VW system are shown in figure 3. To access care through the system, staff and their immediate relatives with symptoms of COVID-19 or those who have had significant contact with a confirmed case are advised to call the staff COVID-19 hotline (ie, the internal hotline which operates 24 hours a day, 7 days a week) about their symptoms and for general enquiries. The internal COVID-19 hotline is operated by a team of clinicians who use a set of questions and a checklist adapted from the WHO guidelines to triage patients and determine who would require a diagnostic test. A SARS-CoV-2 PCR test is then organised for those who meet the requirements and results are communicated to them within the next 12–24 hours. The subsequent pathway of care (ie, virtual care or hospital admission) is determined based on the individual’s test result and severity of symptoms.

All patients confirmed COVID-19-positive and who qualify for virtual care are assigned an SCRIC physician and provided with a digital thermometer to monitor daily axillary temperature. Pulse oximeter are provided on a case-by-case basis to aid the monitoring of oxygen saturation. Pulse oximeters are given to patients who have a significant background medical condition, those who are above 55 years, or those considered by their assigned physician to have a high risk of respiratory deterioration. The assigned SCRIC physician adopts a virtual monitoring
plan based on standard COVID-19 care guidelines and provides additional support as required during scheduled follow-up teleconsultation. The temperatures and oxygen saturation readings taken by the patients are fed back to physician during each ‘VW rounds’, and patients are also instructed to immediately call the SCRIC physician if their readings were above or below certain predetermined thresholds. The VW system also provides a safe accommodation on site (ie, within the MRCG at LSHTM facilities) for staff isolation where home circumstances were not suitable for home isolation. If any patient in the VW developed severe symptoms, they were reviewed and transferred to the MRCG at LSHTM CSD for inpatient hospital care.

From 24 August 2020 when the VW became operational to 31 April 2021, 427 patients who are COVID-19 positive (MRCG at LSHTM staff and their relatives) have been admitted, followed-up and discharged through the VW system. Of these, 75% (321/427) were staff, while 25% (106/427) were immediate relatives of staff (table 1).

So far, about 2% of the 427 cases managed through the system developed severe disease warranting in-hospital care and were transferred to the MRCG at LSHTM CSD. So far, all the cases with severe disease have been successfully managed in the CSD, transferred back into the VW and discharged from follow-up in the VW with no mortality recorded.

THE COMPOSITION AND FUNCTION OF THE TEAM

To ensure the effective operation of the VW system, and provide quality COVID-19 follow-up and care, we constituted a multidisciplinary team made up of a cross-section of clinical staff (14 physicians and 10 nurses who are duly registered as practitioners in The Gambia), four project management and administrative staff, and a dedicated ambulance driver. Furthermore, we leveraged existing structures within the MRCG at LSHTM, working closely with our CSD, health and safety department, and clinical and research laboratories, which also continue to support the national SARS-CoV-2 PCR testing throughout the country.

The physicians on the team are responsible for communicating with known contacts of cases to confirm exposure, organise for such contacts to undergo a diagnostic test 3–5 days after the last known exposure, communicate positive results and provide clinical assessment and care during the VW round. The nursing staff collect the diagnostic nasopharyngeal and oropharyngeal swabs on an outpatient basis at the MRCG at LSHTM and transport samples to the clinical laboratory for SARS-CoV-2 PCR testing. The project management and administrative staff handle data entry, non-clinical communication and ensure smooth day-to-day running of the system. The ambulance drivers are on hand to provide safe transport...
for patients who may require transfer from their homes to the CSD for testing, or clinical evaluation if their clinical condition necessitates a transfer at any time during their follow-up.

At the beginning of the pandemic, physicians who found themselves away from The Gambia and unable to return due to travel restrictions at the time were drafted into the team if they wished to support the VW system. This was possible because of the virtual nature of our system, which enabled our physicians to provide care for patients with COVID-19 remotely. We have also been able to leverage the services of other physicians among our staff who are unable to provide face-to-face clinical services or continue with research activities because they have been assessed to be at risk for severe COVID-19 as a result of their background medical condition that warrants their shielding. Through this approach, we have been able to operate a diverse team of physicians with varied experience and located across three continents (Africa, Europe and North America). Thus, we continue to use critical clinical manpower that would have ordinarily not been available and complement the clinical care provided by the team on the ground in The Gambia as the pandemic continues.

**CLINICAL OVERSIGHT**

An assigned physician member of the team (ie, an individual who is medically qualified to provide clinical patient care and registered in The Gambia) has primary clinical oversight for each patient being followed-up through the VW system. To ensure consistency of the process and continuity of care provided, each patient had one SCRIC physician assigned to them from admission through the VW until they are discharged from follow-up. There is evidence suggesting that such an approach to follow-up helps in building trust between doctor and patient, and also allays patient’s anxiety—an outcome which is desired as the COVID-19 pandemic continues to evolve. The SCRIC clinical team operates a rota system, which ensures that one clinical consultant on the team is placed on call per week and has overall oversight for all the patients being followed-up in the VW during their period of call.

Should a patient’s clinical condition warrant additional review, it is the responsibility of the managing SCRIC physician to discuss their assigned patient with the SCRIC consultant on-call and make key clinical management decisions together. Where a patient’s symptoms progresses and warrant inpatient care, the SCRIC consultant on-call discusses the case with the CSD consultant that is responsible for providing inpatient management for severe patients with COVID-19 admitted to the CSD of the MRCG at LSHTM. A joint decision (between the SCRIC consultant and the CSD consultant) is reached before such patients are transferred for inpatient clinical care. Once patients are transferred from the VW system to the CSD for inpatient care, the CSD team takes over clinical oversight and manages the patients according to the CSD COVID-19 clinical guidelines for inpatients. Patients discharged from in-hospital care after the successful management of their severe disease at the CSD are also discussed with the SCRIC consultant on-call by the CSD consultants before being transferred to continue care in the VW system.

**CLINICAL STANDARD OPERATING PROCEDURES AND GUIDELINES**

There is evidence supporting the potential positive impact of clinical guidelines and standard operating procedures (SOPs), on improving the quality and the consistency of care provided by teams of clinicians to patients. The SCRIC team developed SOPs and guidelines, which provides clear and stepwise processes and govern all the aspects of care that the team provides (see Box 1). These guideline documents clearly specify team members’ responsibilities and provide a detailed and stepwise description of each process. Example of issues covered by these SOPs and guidelines include how staff can access the system, how and when swabbing for SARS-CoV-2 swabbing is arranged, what clinical information to be collected before and after a test to aid informed decisions, who communicates test results and how this should be done. There are also guidelines on how the initial triage of patient is to be is conducted (online supplemental appendix 1), what criteria determines if a patient would require hospital care rather than a virtual follow-up, how and when the subsequent follow-up should be conducted and the process of terminating virtual follow-up.

At the outset, we prioritised the drafting of these guidelines and the training of team members to ensure they were comfortable with them before their implementation. All guidelines are drafted and are continuously updated in line with the best available evidence at the time, current WHO COVID-19 guidelines and recommendations, and put into the context of the prevailing national guidelines being implemented in The Gambia.

---

Box 1  Example of clinical guidelines and SOPs developed for the virtual ward (VW) system

- Guideline for initial triage of patients.
- Guideline specifying how and when SARS-CoV-2 testing is arranged.
- Standard operating procedure (SOP) on the communication of SARS-CoV-2 test results to patients.
- Flowchart to aid decision on pathway of care after a positive result.
- SOP for virtual clinical assessment and follow up visits for patients who are COVID-19 positive.
- Guideline for the transfer of patients between the VW and inpatient COVID-19 care.
- Guideline for discharging patients with COVID-19 from the VW.

---

TELECONSULTATION AND COMMUNICATION SYSTEMS
To conduct virtual consultation and follow-up, we relied on mobile telephones and messaging applications such as WhatsApp. Most members of staff at the MRCG at LSHTM are connected by a closed user group on their mobile phones through a local telecommunication service provider; hence, the default mode of teleconsultation and communication between team members was the use of mobile telephones. However, ‘VW rounds’ were also conducted through WhatsApp by our team of physicians who were outside The Gambia and in scenarios where video consultation was explicitly required by the team on the ground. We resorted to the use of WhatsApp as a telecommunication tool in these scenarios because it is an inexpensive solution suitable for our physicians abroad who faced prohibitive cost of international phone. Additionally, WhatsApp video-conferencing offered a platform and the ability to conduct a more complete clinical assessment. Although internet penetration (ie, individuals using the internet) was about 20% of the general Gambian population as of January 2020, the much higher internet penetration for staff members of the MRCG at LSHTM made the use of the video-conferencing option more feasible.

DATA CAPTURE AND MANAGEMENT
To ensure a seamless virtual management of patients with COVID-19 by our team working remotely together, we use the Research Electronic Data Capture (REDCap) database to capture, share and securely store patient data. REDCap is a web-based application that provides a highly secured environment, suitable for storage of sensitive patient information and which is intuitive to use for research and clinical teams. The database was designed by the MRCG at LSHTM data management team, in collaboration with the SCRIC team and all the clinical team members have remote access to the database. Patient data captured in the database include basic biodata, history of contact/exposure to confirmed cases, symptomatology, background medical conditions and results of all SARS-Cov-2 tests conducted. We also capture all clinical notes and decisions made throughout the virtual follow-up process.

LIMITATIONS AND CHALLENGES OF THE VIRTUAL WARD SYSTEM
The implementation and sustainability of our VW system has been subject to two main challenges. The first has been maintaining optimal staffing to operate the VW system. At the time the system was implemented at the peak of the first wave of the pandemic in The Gambia in mid-2020, most non-essential activities in our unit had been halted thereby enabling secondment of some of the clinical and non-clinical staff from their primary research, and administrative roles to support the system. With the resumption of normal duties after the first wave, many staff have returned to their routine duties. Although they still continue to provide some support, the demands of their routine workloads limits how much support they can reasonably provide. The second challenge has been securing continued funding to sustain the additional staffing, consumables and logistics requirement for the system. Financial resources are finite, even more so during a pandemic, which continue to stretch to the limits existing budget lines. An economic analyses of the VW will be useful to highlight the utility and potential cost savings, or the additional cost of operating the VW system.

POTENTIAL IMPLEMENTATION AND OPERATIONAL CHALLENGES FOR OTHER SETTINGS
For the successful establishment and operation of the VW in other resource-limited settings, there are potential implementation bottlenecks that must be considered. First, internet penetration in most resource-limited setting is sometimes patchy and could impede the success of the VW system, especially for video-conferencing and electronic data capture. How poor internet penetration and low quality bandwidth hampers the feasibility and utility of remote healthcare delivery models in sub-Saharan is well documented. We overcame this operational challenge because internet penetration is generally high among the cohort of people the system supported and the MRCG at LSHTM has an excellent network infrastructure, the use of the paper-based diaries and phone call VW models could bridge this gap even as the pandemic evolve across Africa.

Second, although this VW system has worked well so far in our setting, as mentioned above, it is not without cost to the MRCG at LSHTM. While many VW systems are embedded within existing healthcare budgets, ensuring their long-term sustainability requires additional funding. Thus, detailed budgeting for additional cost such as data capture systems, telephone communication, internet charges, consumables (thermometers, pulse oximeters, etc) and logistics must be considered before the implementation of the VW system. This is even more important especially in sub-Saharan Africa, where such cost is often not equitably budget for at primary-level and secondary-level public healthcare facilities.

Third, the VW requires HRH who can dedicate time to run the system. Similar to the model we operated, during the COVID-19 pandemic, many VW systems in high-income countries reallocated HRH from non-emergency clinical setting to support the implementation of the model. Nevertheless, HRH in many low-income and middle-income countries is limited and they are already overstretched from supporting in-hospital care for COVID-19 and other diseases, thus, potentially limiting their availability to support a VW system. The feasibility of implementing VWs in sub-Saharan Africa requires that
careful attention be paid to the potential implementation challenges we have highlighted above. Ultimately, even in high-income countries, the sustainability of VW systems to provide care for patients with COVID-19 in the future will depend on how these challenges are navigated.

CONCLUSION
We have described the processes involved in setting up and operating a successful VW system at the MRCG at LSHTM to manage staff and their family members who developed asymptomatic, mild or moderate COVID-19. We demonstrate that a VW system for the care of patients with COVID-19 in non-hospital setting is feasible in a low-income country in west Africa. We believe that other low-income or resource-constrained settings can adopt and contextualise the processes described here to safely support patients with COVID-19 in non-hospital settings.

Author affiliations
1Vaccines and Immunity Theme, Medical Research Council Unit, The Gambia at London School of Hygiene and Tropical Medicine, Banjul, The Gambia
2Nutrition Theme, Medical Research Council Unit, The Gambia at London School of Hygiene and Tropical Medicine, Banjul, The Gambia
3Disease Control and Elimination, Medical Research Council Unit The Gambia, at London School of Hygiene and Tropical Medicine, Banjul, Gambia
4Clinical Services Department, Medical Research Council Unit The Gambia, at London School of Hygiene and Tropical Medicine, Banjul, Gambia
5Data Management and Archives, Medical Research Council Unit The Gambia, at London School of Hygiene and Tropical Medicine, Banjul, Gambia
6Directorate, Medical Research Council Unit The Gambia, at London School of Hygiene and Tropical Medicine, Banjul, Gambia
7Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK

Twitter Oghenebrume Wariri @drwariri

Contributors All named authors made substantial contributions to establishing/operating the virtual ward (VW), or the conceptualisation of the practice paper, or the drafting of the manuscript, and critically reviewing the manuscript. OW led the implementation and coordination of the VW during the first wave of COVID-19 in the Gambia and conceptualised the idea for this practice paper. All authors approved the final version and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Funding The work reported here was supported by funding from the European Commission (reference number: FED/2020/417-470) through the ‘Support and strengthen the public health and socioeconomic systems to reduce the impact of the Covid-19 pandemic in The Gambia’. HB was supported by Wellcome Trust (reference number: 200116/Z/15/Z) as a clinical COVID-19 secondment. The funder had no role in the design or the reporting of this work.

Disclaimer The views expressed in this practice paper are those of the authors and do not necessarily reflect those of their parent organisation: The Medical Research Council Unit The Gambia at London School of Hygiene and Tropical Medicine.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement There are no data in this work.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iD Oghenebrume Wariri http://orcid.org/0000-0002-7432-8995

REFERENCES


CHECKLIST FOR INITIAL TRIAGE AND REVIEW OF STAFF AND THEIR RELATIVE

WHO TESTED POSITIVE FOR COVID-19

Disclosure of positive results to staff and their relatives should be done confidentially and with empathy considering the effect such news may have on the person.

INFORMATION TO BE OBTAINED

1. History of background/ underlying disease/ immunocompromised state.
2. Presence of ongoing symptoms and history of symptoms in the past. (History of symptoms with date of onset, severity of symptoms especially respiratory symptoms and the diurnal pattern of body temperature/fever).
   a) If symptoms are ongoing; self-isolation period will be for 13 days; if after 13 days symptoms still persist or new symptoms develop within the isolation period (fever, respiratory symptoms), the period is extended until the staff or relative is symptom free for 3 days (see appendix 1). For a staff who previously had symptoms, but on the day of result disclosure is currently asymptomatic, rule (2b) applies
   b) For asymptomatic staff/relative who do not develop any symptom in the course of self-isolation, the period of self-isolation is for 10 days
   c) For the “significant contacts” of the staff or relative, they proceed for quarantine for 14 days (see appendix 1), and if any of them develop symptoms they are tested,
      a. if positive they will be treated as in case (2a),
      b. if negative they complete the 14 days self-isolation.

3. Home setting/social factors
   a) Number of rooms in the house
   b) Number of persons who live in the house (under the same roof)
   c) Room occupancy pattern (the number of people sleeping in a room, distribution of rooms within the family members).
   d) Number of convenience present and the number of persons who use the convenience
   e) Activities done in common in the house (Eating together, playing games, amongst others)
   f) Number of persons in the compound and the interactions between them (the activities they do in common).
   g) Anyone in the compound with COVID-relevant underlying conditions?

INFORMATION DISCLOSED TO COVID-19 POSITIVE STAFF AND RELATIVES

1. The Result (Positive, Indeterminate*, Negative).
2. The meaning of the result and ensure feedback is gotten from the staff or relative that they understand the information just given.
3. Based on information obtained, asymptomatic, mild, and moderate cases of COVID-19 are told to proceed on self-isolation.

Staff COVID-19 Risk Coordination Team SCRIC
The expected duration of self-isolation for the staff/relative and the contacts in the house is communicated.

During this time, MRC clinicians from the SCRIC team will keep in touch with staff and their relatives to monitor their condition and ensure self-isolation at home continues to be appropriate; and in case of deterioration an admission to CSD or a treatment Centre will be considered.

Rules of self-isolation are explained to them

- Sleeping alone in a room and spending as much time as possible alone in this room
- Not leaving the compound during the self-isolation period
- Use of facemask in the house or when talking to others
- Regular washing of hands with soap and water especially after touching commonly used surfaces like door handles etc.
- Disinfecting frequently touched surfaces and the floor with sodium hypochlorite (bleach) in water
- Maintaining at least “2m” from contacts in the home and within the compound
- Exposure to early morning sun within the compound
- Eating a balanced diet
- Adequate aeration and ventilation of the rooms in the house
- Proper hydration
- Rest
- The need to communicate to the assigned follow-up doctors if a new symptom develops or a “Significant contact” develops a symptom and requires testing
- Taking of paracetamol as antipyretics, and analgesic if the need arises.

Name of Project/Department and contact details of their line manager (name, email) - only applicable to staff. Note that staff should be told that their line managers would be informed about their status or that of their relative if it affects their mobility for purposes of contact tracing and so that they can be excused from duty for the duration of isolation.

Staff is told to inform their line manager

*Note: for indeterminate result, the staff/relative is asked to re-swabbed 2 days later.

**ACTIONS TO BE TAKEN AFTER SPEAKING WITH THE STAFF OR RELATIVE**

1. **Send an email to the line manager** of the affected staff and copy in HR. This does not apply to patient relatives per se, but only if it affects the staff in their mobility due to isolation requirements.

2. Complete the section on REDCap and check the box which indicates that the line manager has been informed

3. **Assign the staff or their relative** to a specific SCRIC physician by adding their names to the page of the assigned physician on the live SCRIC daily follow-up excel sheet

4. If a staff or their relative needs to isolate at the MRC, the nurse coordinator on the SCRIC team (Mr Bunja-2954157) should be informed to make this arrangement.

Staff COVID-19 Risk Coordination Team SCRIC
If a staff or their relative needs to be admitted to the CSD, discuss with the SCRIC consultant on call for the week and agree on the decision before reaching out to the CSD COVID consultant on call. Names and numbers of the CSD COVID consultant on call shall be provided weekly to the SCRIC team.

| Written by: | Name: Emmanuel Okoh | Date: 23 July 2020 |
| Reviewed by: | Name: Oghenebrume Wariri | Date: 26 July 2020 |
| Reviewed by: | Name: Hawanatu Jah | Date: 26 July 2020 |
| Version: | Change history: | Review due date: |
| 1.0 | New document | 26 July 2022 |

Review Comments (if applicable)